Jiangbo Pharmaceuticals, Inc., a researcher, developer, producer and marketer of pharmaceutical products in China, recently announced that the company’s Osteomyelitis treatment tablets have been included in the 2009 Edition of the National Basic Medical Insurance, Industrial Injury Insurance and Maternity Insurance Medicine Directory.

Also referred to as Kang Gu Sui Yan Pian, the company’s Osteomyelitis treatment tablets are 100 percent herb-based traditional Chinese medicine used to treat bone and bone marrow inflammations. As the exclusive manufacturer of Osteomyelitis treatment tablets in China, the company’s tablets offer a milder treatment option compared to chemical drugs for treating long-term osteomyelitis problems. Along with Kang Gu Sui Yan Pian, four additional Jiangbo products have been included in the National Basic Medical Insurance, Industrial Injury Insurance and Maternity Insurance Medicine Directory, including Radix Isatidis Granules, Motherwort Herb Electuary, Ciprofloxacin Hydrochloride tablets and Paracetamol tablets.

Mr. Wubo Cao, Jiangbo Pharmaceuticals’ chief executive officer, stated, “The inclusion of Osteomyelitis treatment tablets in the 2009 Edition Directory is an important accomplishment for our company.” Mr. Cao continued, “As its exclusive manufacture, we expect the inclusion of Osteomyelitis treatment tablets in the Directory to drive meaningful sales volume growth in future.”